Astrazeneca plc

AZNNYSE · USD
178.76USD0.00 (-1.93%)
689

Astrazeneca plc (AZN) Option Chain

Astrazeneca plc trades at $178.76, down 1.93%, with an IV Rank of 19.84%. This is low versus the past year, and the company carries a market cap of $277,242M in the Drug Manufacturers - General industry. On the Nov 20, 2026 chain, the at the money $180.00 strike shows calls at $0.75 / $1.35 and puts at $2.20 / $3.00, both carrying about $1.20 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $185.00 calls, at 616 contracts, and the $180.00 puts, at 648, as of Nov 18, 2026.

Read more

Tracking the AZN option chain helps you see every strike and expiry on Astrazeneca plc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of AZN options activity at a glance. Use our scanner to monitor the AZN option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For AZN stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where AZN options are being actively traded, and where they are not.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
0.312,44710.448.768.709.70170.00-4.900.050.200.000.13656999.69
12.361,58020.793.764.005.10175.00-2.100.400.550.000.482671287.64
64.591,8111721.050.000.751.35180.00+0.692.203.001.241.3664821735.41
96.881,0846160.180.000.100.25185.00+3.495.507.106.240.06166093.12
99.9568420.150.00—0.15190.00+6.299.9012.5011.24-0.040970.05

As of Nov 18, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - General
  • SectorHealthcare
  • IV Rank19.84% Low
  • Market cap (M$)277,242
  • 52 weeks high-15.96%
  • 52 weeks low16.52%
  • Analyst recommendationStrong Buy
    1.50
  • Target price$228.71
    27.94% above the current stock price
  • Dividend—
  • Payout ratio47.19%
  • Earnings date2027-02-09
  • P/E25.30
  • Future P/E15.73
  • EPS (ttm)7.07
  • EPS growth next 5 years11.21%

As of Nov 18, 2026